ARGX Latest Press Releases

-- October 22, 2026 --

argenx Reports Third Quarter 2026 Financial Results and Provides Business Update Globe Newswire 1:00 AM

-- October 19, 2026 --

argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026 Globe Newswire 8:00 AM

-- October 15, 2026 --

argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026 Globe Newswire 1:00 AM

-- October 12, 2026 --

ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law Business Wire 4:24 PM

-- October 8, 2026 --

argenx Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into argenx (ARGX) PRNewswire 4:34 PM

argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease Globe Newswire 1:00 AM

argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjgren's Disease Globe Newswire 1:00 AM

-- September 29, 2026 --

argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline Globe Newswire 8:00 AM

-- September 17, 2026 --

argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors Globe Newswire 4:02 PM

-- September 1, 2026 --

argenx to Present at Upcoming Investor Conferences Globe Newswire 1:00 AM

-- August 27, 2026 --

argenx Completes Acquisition of Forte Biosciences, Inc. Globe Newswire 8:50 AM

-- August 17, 2026 --

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis Business Wire 6:00 AM

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis Globe Newswire 1:00 AM

-- August 11, 2026 --

Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX Business Wire 11:56 AM

-- August 6, 2026 --

argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc. Globe Newswire 7:48 AM

-- August 3, 2026 --

argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026 Globe Newswire 4:01 PM

-- July 28, 2026 --

Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX Business Wire 2:15 PM

-- July 27, 2026 --

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline Business Wire 1:07 AM

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline Globe Newswire 1:00 AM

-- July 23, 2026 --

argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update Globe Newswire 1:00 AM

-- July 16, 2026 --

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026 Globe Newswire 1:00 AM

-- June 23, 2026 --

argenx to Host Autoimmune Myositis R&D Webinar Globe Newswire 1:00 AM

-- June 3, 2026 --

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026 Globe Newswire 1:00 AM

-- May 28, 2026 --

argenx to Host Myositis R&D Webinar on June 23, 2026 Globe Newswire 1:00 AM

-- May 27, 2026 --

argenx to Present at Upcoming Investor Conferences Globe Newswire 1:00 AM

Market Data Delayed 15 Minutes